Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Black Diamond Therapeutics’ (NASDAQ: BDTX) BDTX-1535 Proves Promising for EGFR Mutated NSCLC and GBM

Black Diamond Therapeutics has announced encouraging initial data from a Phase 1 study of BDTX-1535, an investigational fourth-generation EGFR MasterKey inhibitor. The trial targets patients with non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM) with acquired and intrinsic driver EGFR mutations.

Key Findings from the Phase 1 Study of BDTX-1535

The study showed clinical proof of BDTX-1535’s efficacy in NSCLC patients. Partial response, confirmed by RECIST 1.1, was observed in 5 out of 12 NSCLC patients treated with predicted therapeutic doses. Another patient showed unconfirmed partial response, while six others exhibited stable disease.

BDTX-1535 exhibited a favorable tolerability profile, supporting its exploration in NSCLC expansion cohorts. Anticipated updates on the GBM cohort from the Phase 1 dose escalation data are due in Q4 2023.

BDTX-1535 Phase 1 Study Design and Initial Results

This first-in-human open-label clinical trial of BDTX-1535 involved dose escalation, followed by dose expansion cohorts. The study assessed the safety, pharmacokinetics, and preliminary anti-tumor activity of BDTX-1535 in adult patients with advanced/metastatic NSCLC or recurrent GBM expressing EGFR alterations.

As of May 20, 2023, 51 patients had been treated with BDTX-1535, exhibiting a linear increase in exposure and a half-life of approximately 15 hours. The drug was well-tolerated by NSCLC and GBM patients, and the overall safety profile was consistent with the EGFR tyrosine kinase inhibitor (TKI) class of drugs.

Promising Results Spur Further Investigation

Based on the data gathered, Black Diamond Therapeutics plans to commence enrollment at the BDTX-1535 200 mg daily dose in two expansion cohorts of NSCLC patients who had received up to two prior lines of therapy, including a third-generation EGFR TKI.

Upcoming Milestones for BDTX-1535

Black Diamond Therapeutics has outlined several significant milestones for BDTX-1535. These include the initiation of dose expansion cohorts in H2 2023, presentation of the full BDTX-1535 dose escalation data at a medical conference in Q4 2023, and a meeting with the FDA to discuss potential accelerated approval pathways for NSCLC in the same quarter. Furthermore, an update on the BDTX-1535 Phase 1 dose escalation data for recurrent GBM patients is expected in Q4 2023.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Black Diamond Therapeutics’ (NASDAQ: BDTX) BDTX-1535 Proves Promising for EGFR Mutated NSCLC and GBM appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.